

Update to Capital Structure Records

Melbourne, Australia – 24 June 2026: Leading digital health company, Adherium Limited (ASX: ADR) advises that certain updates will be made to the Company's capital structure records maintained by ASX to ensure they accurately reflect the securities currently on issue.

The following amendments will be made:

- The number of **ADRAX** options on issue will decrease by 20,000,000.
- The number of **ADRAW** options on issue will increase by 20,000,000.

The adjustment relates to the classification of 20,000,000 options that were previously exercised into ordinary shares and does not affect the total number of securities on issue, the rights attaching to those securities, or the Company's issued share capital.

The Company's capital structure will be updated to reflect these amendments.

The Company confirms that these changes are administrative in nature only and have no material impact on the Company's issued capital, security holders or previously announced securities transactions.

Late Lodgement of Appendix 3G

ADR refers to the Appendix 3G lodged following this announcement in respect of unlisted options granted to employees under the Company's Employee Share Scheme. Following review of historical employee incentive grants, the Company identified that due to an administrative oversight an Appendix 3G had not previously been lodged in relation to certain employee options granted in September 2025 and February 2026. The Company has now lodged the Appendix 3G to update the market and ensure its ASX records are complete.

The Company has reviewed its processes and considers them appropriate to ensure ongoing compliance with the ASX Listing Rules.

This ASX announcement was approved and authorised for release by the Company Secretary of Adherium.

- ENDS -



ASX Release

Investor Enquiries

Adherium Limited

investors@adherium.com

Media Enquiries:

Haley Chartres

HACK Director

haley@hck.digital

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally.

Adherium's Hailie[®] platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie[®] solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie[®] solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. Learn more at

adherium.com